478 related articles for article (PubMed ID: 20127862)
21. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
[TBL] [Abstract][Full Text] [Related]
22. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
23. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
24. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
25. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Richon V; Ni X; Talpur R; Duvic M
J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
[TBL] [Abstract][Full Text] [Related]
26. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Atadja P
Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
[TBL] [Abstract][Full Text] [Related]
27. Panobinostat in lymphoid and myeloid malignancies.
Khot A; Dickinson M; Prince HM
Expert Opin Investig Drugs; 2013 Sep; 22(9):1211-23. PubMed ID: 23826641
[TBL] [Abstract][Full Text] [Related]
28. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
29. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
30. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma.
Jeon YJ; Ko SM; Cho JH; Chae JI; Shim JH
Int J Mol Med; 2013 Oct; 32(4):860-6. PubMed ID: 23877235
[TBL] [Abstract][Full Text] [Related]
31. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
Floris G; Debiec-Rychter M; Sciot R; Stefan C; Fieuws S; Machiels K; Atadja P; Wozniak A; Faa G; Schöffski P
Clin Cancer Res; 2009 Jun; 15(12):4066-76. PubMed ID: 19509176
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.
Di Fazio P; Montalbano R; Neureiter D; Alinger B; Schmidt A; Merkel AL; Quint K; Ocker M
Exp Cell Res; 2012 Sep; 318(15):1832-43. PubMed ID: 22683924
[TBL] [Abstract][Full Text] [Related]
33. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
34. LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression.
Yao ZG; Li WH; Hua F; Cheng HX; Zhao MQ; Sun XC; Qin YJ; Li JM
J Neuropathol Exp Neurol; 2017 Dec; 76(12):1000-1007. PubMed ID: 29136455
[TBL] [Abstract][Full Text] [Related]
35. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
36. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
37. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
38. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
Lin Z; Zhang Z; Jiang X; Kou X; Bao Y; Liu H; Sun F; Ling S; Qin N; Jiang L; Yang Y
Oncotarget; 2017 Mar; 8(11):17833-17848. PubMed ID: 28147319
[TBL] [Abstract][Full Text] [Related]
39. MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo.
Ye P; Zhao L; McGirr C; Gonda TJ
Cancer Lett; 2014 Feb; 343(1):98-106. PubMed ID: 24075958
[TBL] [Abstract][Full Text] [Related]
40. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]